Abstract

Chronic obstructive pulmonary disease (COPD) is a disease characterized by abnormalities in ventilation, including disturbances in the airflow channel. In case this patient is 58 years old with a diagnosis of chronic obstructive pulmonary disease, acute exacerbation (COPD AE), Heart Failure (HF), Coronary Artery Disease (CAD), Hypokalemia, Hypoalbumin. When treated in the intensive care unit (ICU) patient experiencing HAP pneumonia and septic condition, with blood sugar at 324, and use insulin later in an empirical patient treated with antifungal Fluconazole infusion, from the drugs used, researchers need to examine whether fluconazole and insulin are used in the therapy of septic conditions with diabetes. After conducting a literature review of the use of fluconazole infusion and insulin in patients with septic condition cases, things This done to prevent the occurrence of death in patients treated in the ICU. Fluconazole and insulin in the treatment of ICU patients with septic conditions have an appropriate level for preventing death.

There is no Figure or data content available for this article

References

• 1. Prasad B. Chronic Obstructive Pulmonary Disease (COPD). 67| International Journal of Pharmacy Research & Technology. 10(1). doi:10.31838/ijprt/10.01.12
• 2. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y
• 3. Liao KM, Lin TC, Li CY, Yang YHK. Dementia Increases Severe Sepsis and Mortality in Hospitalized Patients With Chronic Obstructive Pulmonary Disease. Medicine. 2015;94(23):e967. doi:10.1097/MD.0000000000000967
• 4. Mahapatra S, Heffner AC. Septic Shock. 2026.
• 5. Schorr C, Odden A, Evans L, et al. Implementation of a multicenter performance improvement program for early detection and treatment of severe sepsis in general medical–surgical wards. J Hosp Med. 2016;11(S1). doi:10.1002/jhm.2656
• 6. Islam MdM, Nasrin T, Walther BA, Wu CC, Yang HC, Li YC. Prediction of sepsis patients using machine learning approach: A meta-analysis. Comput Methods Programs Biomed. 2019;170:1-9. doi:10.1016/j.cmpb.2018.12.027
• 7. Napolitano LM. Sepsis 2018: Definitions and Guideline Changes. Surg Infect (Larchmt). 2018;19(2):117-125. doi:10.1089/sur.2017.278
• 8. Lueangarun S, Leelarasamee A. Impact of Inappropriate Empiric Antimicrobial Therapy on Mortality of Septic Patients with Bacteremia: A Retrospective Study. Interdiscip Perspect Infect Dis. 2012;2012:1-13. doi:10.1155/2012/765205
• 9. Kim WY, Lee YJ, Yeon Lim S, et al. Clinical characteristics and prognosis of pneumonia and sepsis: multicenter study. Minerva Anestesiol. 2013;79(12):1356-1365.
• 10. Jacobs S, Price Evans DA, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: A randomized double-blind prospective study. Crit Care Med. 2003;31(7):1938-1946. doi:10.1097/01.CCM.0000074724.71242.88
• 11. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85-96. doi:10.1038/nrm1837
• 12. Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab. 2001;15(4):533-551. doi:10.1053/beem.2001.0168
• 13. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. The Lancet. 2009;373(9677):1798-1807. doi:10.1016/S0140-6736(09)60553-5
• 14. Barth E, Albuszies G, Baumgart K, et al. Glucose metabolism and catecholamines. Crit Care Med. 2007;35(Suppl):S508-S518. doi:10.1097/01.CCM.0000278047.06965.20
• 15. Aleman L, Guerrero J. Hiperglicemia por sepsis: del mecanismo a la clínica. Rev Med Chil. 2018;146(4):502-510. doi:10.4067/s0034-98872018000400502
• 16. Wang L, Wang M, Du J, Gong Z cheng. Intensive insulin therapy in sepsis patients: Better data enables better intervention. Heliyon. 2023;9(3):e14063. doi:10.1016/j.heliyon.2023.e14063

There is no Supplemental content for this article.

How to Cite This

Article Metrics

Copyright and Permissions

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

• BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability